Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis | 6 | 2023 | 63 | 1.970 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2018 | 105 | 1.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2018 | 473 | 1.160 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2021 | 112 | 0.730 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2024 | 126 | 0.660 |
Why?
|
| Granuloma | 2 | 2016 | 67 | 0.620 |
Why?
|
| Interleukin-17 | 1 | 2018 | 118 | 0.590 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 26 | 0.560 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 216 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2022 | 490 | 0.530 |
Why?
|
| Up-Regulation | 2 | 2018 | 867 | 0.530 |
Why?
|
| Anti-Infective Agents | 2 | 2016 | 266 | 0.520 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2021 | 428 | 0.500 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 77 | 0.480 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 322 | 0.470 |
Why?
|
| Fibroblasts | 4 | 2024 | 878 | 0.460 |
Why?
|
| Organotin Compounds | 1 | 2013 | 6 | 0.450 |
Why?
|
| Trialkyltin Compounds | 1 | 2013 | 7 | 0.440 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 155 | 0.410 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 206 | 0.410 |
Why?
|
| Gene Expression Regulation | 6 | 2022 | 2530 | 0.330 |
Why?
|
| Signal Transduction | 4 | 2021 | 4494 | 0.310 |
Why?
|
| Bleomycin | 4 | 2024 | 150 | 0.300 |
Why?
|
| Sarcoidosis, Pulmonary | 2 | 2017 | 11 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2024 | 130 | 0.260 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2307 | 0.250 |
Why?
|
| Lung | 4 | 2024 | 1474 | 0.250 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2024 | 17 | 0.240 |
Why?
|
| Syndecan-2 | 2 | 2022 | 14 | 0.240 |
Why?
|
| Autophagy | 2 | 2024 | 391 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 85 | 0.220 |
Why?
|
| Fibrosis | 1 | 2024 | 429 | 0.200 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 409 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2022 | 96 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 396 | 0.180 |
Why?
|
| Lung Injury | 1 | 2022 | 122 | 0.170 |
Why?
|
| Apoptosis | 2 | 2024 | 1781 | 0.170 |
Why?
|
| Demography | 2 | 2017 | 239 | 0.160 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 254 | 0.160 |
Why?
|
| Collagen Type I | 1 | 2018 | 110 | 0.150 |
Why?
|
| Mice | 7 | 2024 | 17486 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2018 | 90 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2017 | 152 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2017 | 3251 | 0.120 |
Why?
|
| Humans | 15 | 2024 | 123146 | 0.120 |
Why?
|
| Flame Retardants | 1 | 2014 | 2 | 0.120 |
Why?
|
| Polybrominated Biphenyls | 1 | 2014 | 4 | 0.120 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2014 | 7 | 0.120 |
Why?
|
| Antimalarials | 1 | 2015 | 37 | 0.120 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 123 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1515 | 0.120 |
Why?
|
| Aged | 5 | 2018 | 19068 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 352 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2013 | 15 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 99 | 0.110 |
Why?
|
| Animals | 7 | 2024 | 33719 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 83 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1682 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2014 | 1611 | 0.110 |
Why?
|
| Ubiquitination | 2 | 2023 | 172 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 317 | 0.100 |
Why?
|
| Middle Aged | 5 | 2018 | 25964 | 0.100 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 2 | 2022 | 10 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2815 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 518 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 667 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4268 | 0.100 |
Why?
|
| Adult | 5 | 2018 | 29029 | 0.090 |
Why?
|
| Male | 8 | 2024 | 60034 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 340 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2024 | 617 | 0.080 |
Why?
|
| Young Adult | 3 | 2017 | 8864 | 0.080 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 101 | 0.080 |
Why?
|
| Female | 6 | 2018 | 65443 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2023 | 3715 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2023 | 37 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2023 | 49 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 117 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 224 | 0.050 |
Why?
|
| Androgens | 1 | 2024 | 256 | 0.050 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2022 | 4 | 0.050 |
Why?
|
| Citrullination | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2022 | 43 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 876 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 232 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 354 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 374 | 0.050 |
Why?
|
| Skin | 1 | 2024 | 505 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2023 | 510 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2021 | 127 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 966 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 455 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 2017 | 5 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2017 | 57 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3277 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2021 | 748 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1907 | 0.030 |
Why?
|
| Mycobacterium | 1 | 2016 | 29 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 2390 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 473 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 678 | 0.030 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2014 | 8 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2014 | 36 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 39 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 48 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 68 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 94 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 481 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 111 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 513 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 370 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 803 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 1283 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3046 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4221 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2023 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 2943 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1580 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 19093 | 0.010 |
Why?
|